10-QPeriod: Q2 FY2019

Medtronic plc Quarterly Report for Q2 Ended Oct 26, 2018

Filed November 29, 2018For Securities:MDT

Summary

Medtronic plc's 10-Q filing for the period ending October 25, 2018, reveals a mixed financial performance. While net sales showed a modest increase year-over-year for both the three and six-month periods, driven by growth in key segments like Cardiac and Vascular, and Diabetes, the company experienced a significant decrease in net income and diluted EPS. This decline was largely attributed to a substantial one-time gain on the sale of businesses in the prior year's comparable period, as well as increased expenses related to restructuring, R&D, and litigation. The company continues to invest in therapy innovation and globalization, with notable growth in emerging markets. However, it also faces ongoing challenges including competitive product launches, pricing pressures, and potential impacts from regulatory changes. Medtronic is actively managing its financial resources, evidenced by a decrease in total debt and strategic share repurchases, while maintaining a strong liquidity position.

Financial Highlights

54 data points
Beta

Revenue

$7.48B

70.6% Gross Margin

Net Income

$1.12B

15.0% Net Margin

EPS (Diluted)

$0.82

Total Assets

$88.15B

Cash & Equivalents

$3.91B

Free Cash Flow

$957.00M

Financial Statements
Beta
Revenue$7.48B
Cost of Revenue$2.20B
Gross Profit$5.28B
SG&A Expenses$2.60B
Operating Income$1.54B
Interest Expense$241.00M
Net Income$1.12B
EPS (Basic)$0.83
EPS (Diluted)$0.82
Shares Outstanding (Basic)1.35B
Shares Outstanding (Diluted)1.36B

Key Highlights

  • 1Total net sales increased by 6% to $7.48 billion for the three months ended October 26, 2018, and by 3% to $14.87 billion for the six months ended October 26, 2018, compared to the prior year periods.
  • 2Net income attributable to Medtronic significantly decreased by 45% to $1.115 billion for the three months and by 28% to $2.190 billion for the six months ended October 26, 2018, primarily due to a large gain on sale of businesses in the prior year.
  • 3Diluted earnings per share (EPS) followed a similar trend, decreasing by 45% to $0.82 for the three months and by 27% to $1.61 for the six months ended October 26, 2018.
  • 4Restructuring charges, net and other associated costs increased significantly, totaling $75 million for the three months and $195 million for the six months ended October 26, 2018, related to the 'Enterprise Excellence' program.
  • 5The Cardiac and Vascular Group and the Diabetes Group showed strong net sales growth, while the Minimally Invasive Therapies Group saw a decrease in net sales for the six-month period, partly due to the divestiture of certain businesses.
  • 6The company reported total debt of $25.0 billion as of October 26, 2018, a decrease from $25.8 billion at April 27, 2018, with no commercial paper outstanding at the end of the period.
  • 7Medtronic continues to repurchase its shares, with approximately $2.0 billion remaining under its share repurchase program as of October 26, 2018.

Frequently Asked Questions

The substantial decrease in net income attributable to Medtronic and diluted EPS is primarily due to a large gain of $697 million on the sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses recognized in the prior year's comparable period. Without this one-time gain, the underlying operational performance shows a different picture.

Medtronic has initiated a multi-year global 'Enterprise Excellence Program' aimed at integrating manufacturing and supply processes, optimizing functions, and streamlining commercial operations. This program is expected to generate significant annual savings but also involves substantial pre-tax restructuring charges, estimated between $1.6 billion and $1.8 billion, with the majority expected by the end of fiscal year 2022.

The Cardiac and Vascular Group and the Diabetes Group are showing strong sales growth, driven by new product launches and demand for advanced systems like the MiniMed 670G. The Cardiac and Vascular Group benefits from innovation in areas like transcatheter aortic valve systems and pacing technologies. The Minimally Invasive Therapies Group experienced a sales decline for the six-month period, partly due to the divestiture of certain businesses, but continues to focus on advanced surgical innovations. Key challenges across segments include competitive product launches, pricing pressures, and navigating evolving reimbursement policies.

Medtronic's total debt has decreased slightly to $25.0 billion as of October 26, 2018. The company has no commercial paper outstanding and maintains a substantial $3.5 billion revolving credit facility, indicating a strong liquidity position. Cash, cash equivalents, and current investments totaled over $10 billion, providing ample resources for operations and strategic initiatives.